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ABSTRACT
Pancreatic carcinoma commonly occur in patients over 60 years. It is usually manifested as abdominal
pain, jaundice, and pancreatic mass. In this report, a pancreatic carcinoma occurred in young woman is
presented. A surgical drainage was done and followed by Whipple resection. However, the patient passed
away three month after the diagnosis.
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INTRODUCTION
Pacreatic cancer is the fourth leading cause of can-
cer death in the United States, killing about 21,000 people
in that country each year. The importance of pancreatic
cancer is further underlined by its extremely bleak prog-
nosis. Regardless of therapy, median survival time is only
about 3 months. The 1-year survival rate is only about
8% and the 5-year rate is about 0-2%.1-3
Incidence rates of pancreatic cancer increase with
advancing age. Approximately 80% of deaths from pan-
creatic cancer occur between ages 60 and 80 years,
and the disease is extremely rare below age 40. Inci-
dence rates in US blacks are higher than in whites and
over the last several decades have increased more in
blacks than in whites.1-4
The cause of pancreatic cancer remains unknown.
The most prominent of the risk factors and possibly the
only one that has been firmly established, is cigarette
smoking. The second most important risk factor appears
to be diet.  A high intake of fat and meat has been linked
to the development of this neoplasm and protective ef-
fect is ascribed to a diet containing fresh fruits and veg-
etables. Occupational exposure to carcinogens (chemi-
cal, petroleum industries) may be associated with pan-
creatic cancer. Diabetes mellitus and chronic pancreati-
tis also predispose to pancreatic cancer.1,6 Hereditary
causes of pancreatic cancer include hereditary pancre-
atitis, perhaps cystic fibrosis, and perhaps a form seen in
southern Asia called tropical pancreatitis. In addition, there
are familial forms of pancreatic cancer in which genetic
defects are inherited, namely, in the p16 tumor suppres-
sor gene (associated with familial melanoma), as well as
in the BRCA2 gene. The latter gene has been associ-
ated with several forms of familial pancreatic cancer.6
Primary malignant epithelial neoplasm of the pancreas
can occur in either the exocrine parenchyma or the en-
docrine cells of the islets of langerhans, but they are far
more frequent in exocrine tissue. Ductal adenocarcinoma
makes up between 75 and 92 percent of pancreatic neo-
plasms. In addition, it is twice as frequent in the head of
the organ as in the body or tail. At the time of diagnosis,
over 85 percent of tumors have extended beyond the
organ.2-4
The signs and symptoms of pancreatic cancer are
nonspecific. Pain, jaundice, or both are present in over
90 percent of patients and these features, in combina-
tion with weight loss, constitute the classic presentation
of the disease.4
· Pain is present either in the abdomen, the back, or
both, in 35%, 8% and 36% of patients, respectively.
The cause of pain, especially of the persistent type,
is usually attributed to invasion of the perineural lym-
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phatics of nerves in and around the pancreas.2,3
· Obstructive jaundice is nearly always associated with
the carcinoma of the head of the pancreas. In 90%
of those with jaundice, it is the invasion of the com-
mon bile duct that causes the obstruction.3
· Weight loss is almost universal in patients with pan-
creatic cancer. It is caused by malabsorbtion, de-
creased calorie consumption, or both.2
· Nonspecific signs and symptoms occur frequently,
such as nausea, vomiting, weakness and anorexia.
Rare findings include superficial thrombophlebitis,
gastrointestinal bleeding, psychiatric disturbance and
diabetes mellitus.2,3
Hepatomegaly and jaundice are present in more than
80% of patients with cancer of the head of the pan-
creas. Pruritus may be a prominent symptom and leads
to persistent scratching, which produces excoriation and
lichenification. Courvoisier sign (palpable gallbaladder)
and abdominal mass are present in 30% and 20%, re-
spectively, of patients with carcinomas of the head of
the pancreas.
In contrast, patients with cancer of the body and tail
of the pancreas may have abdominal tenderness and pain,
but hepatomegaly and jaundice are present in less than
30%. Abdominal mass and ascites occur in less than
20% of the patients.2,3
Diagnosis is most commonly based on imaging stud-
ies of the abdomen, either computed tomography (70-
100%) or ultrasound (80-90%). There is little role for
magnetic resonance imaging in panceatic cancer (1-5%).
ERCP may identify obstruction or encasement of pan-
creatic ducts, and cytology obtained may be diagnostic
(20-40%). 2,7,8 Serologic marker CA 19-9 may be used
to support the diagnosis.7-9
Treatment is based on disease stage. Usually patients
are classified as resectable or unresectable. Only about
20% of diagnosed tumors are resectable.10 Surgical pro-
cedure of choice for resection of tumors of the head of
the pancreas is pancreatoduodenectomy–Whipple’s pro-
cedure–or variations of this procedure.7,11-13 Radiation
therapy is often used with the goals of palliation, local
control or perhaps prolongation of survival. In advanced
cases, it may be used to relieve pain. Current treatment
for resectable disease involves a multi-modality approach
(i.e. surgery followed by adjuvant concurrent chemo-
therapy and radiation therapy). Treatment of locally ad-
vanced disease consists of external beam radiation and
concurrent chemotherapy. For those patients with ad-
vanced disease, best supportive care is as important as
chemotherapy. 5-Fluorouracil (5-FU) and mitomycin C
are usually the agents for palliative purpose.2,4-7 Nowa-
days, gemcitabine is also used. Hopefully, angiogenesis-
inhibitors and gene therapy, therapeutic frontiers of im-
munotherapy, will be able to extend the life span and
improve quality of life of the pancreatic cancer patient.10
CASE REPORT
A 26-years old woman was admitted to Cipto
Mangunkusumo hospital because of jaundice.
The patient had been well until four months earlier,
when abdominal pain and jaundice occurred. The pain
was present in the epigastric region and radiated to the
lumbar region. Her urine became dark and her stools
became light. These complaints were accompanied by
pruritus and weight loss. USG study in Serang hospital
showed gallbladder stones. The patient was then sug-
gested to undergo the operation, but she refused. The
patient chose to try alternative medicine.
Fifteen days prior to admission, the patient had fever,
severe abdominal pain, cough and shortness of breath-
ing. She was hospitalized at Serang hospital and received
blood transfusion because her hemoglobin level was 3.3
g/dL. There was history of melena.
A week prior to admission, the patient was re-hospi-
talized due to severe abdominal pain, jaundice, pruritus
and fever. The patient was referred to Cipto
Mangunkusumo hospital for ERCP.
The patient was a kindergarten teacher in the vil-
lage. Her first son died of retinoblastoma ten month ear-
lier. She did not smoke, but her husband was an active
smoker.
Her temperature was 37 °C, her pulse rate was 96
times per minute and her respiration rate was 24 times
per minute. Her blood pressure was 100/70 mmHg.
On physical examination, the patient was thin and
jaundiced. Her conjunctivae were anemic, and her
sclerae were icteric. Her lungs and heart were normal.
Abdominal examination revealed audible bowel sounds;
there were hepatomegaly, Courvoisier sign and slight
epigastric pain; the spleen was not palpable and no ab-
dominal masses were found. No lymphadenopathy was
found. There was no edema of the leg.
Her hemoglobin level was 8.7 g/dL; leukocyte count
was 15,500. Her urine was dark, with bilirubin +2 and
urobilinogen +4.
Problems considered on admission were cholecysti-
tis, obstructive jaundice and anemia. The patient was
given Cefotaxime 3 X 1 g and a high calorie, low fat
diet. Cholecystitis was based on epigastric pain that ra-
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Table 1. Hematologic laboratory values 
Variable On 
admission 
Fourth 
hospital day 
Tenth 
hospital day 
Hemoglobin (g/dL) 8.7 8.1 11.0 
White-cell count (per mm3) 15,500 16,100 15,400 
Differential count (%)  -/1/1/85/11/2  
Erythrocyte sedimentation rate (mm/hr)  115  
Hematocrit (%) 25 28 31.4 
Platelet count (per mm3) 392,000 529,000 555,000 
Erythrocyte count (per mm3) 3.3 million 3.51 million  
Reticulocyte (%o)  8  
MCV  81  
MCH  23  
MCHC  29  
SI (ug/dL)  327  
TIBC (ug/dL)  368  
Ferritin (ng/mL)  41  
Bleeding time (sec)  4  
Clotting time (sec)  11  
 
Table 2. Blood chemical values 
Variable On 
admission 
Fourth 
hospital day 
Tenth 
hospital day 
Urea nitrogen (mg/dL) 27   
Creatinine (mg/dL) 0.6   
Protein, total (g/dL)  7.1  
Albumin (g/dL)  3.0  
Globulin (g/dL)  4.1  
Bilirubin, total (mg/dL)  27.4  
Bilirubin, direct (mg/dL)  14.5  
Bilirubin, indirect (mg/dL)  12.9  
Alanine aminotransferase (U/L)  124  
Aspartate aminotransferase (U/L)  51  
Phosphatase alkaline (U/L)  1717  
Gamma glutamil transferase (U/L)  364  
Sodium (mmol/L)   113 
Potassium (mmol/L)   38 
Glucose (mg/dL) 190 77  
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diated to lumbar region, fever, jaundice and leukocyto- 
sis. Possible causes in mind were biliary stone or mass 
obstruction. Obstructive jaundice was considered based  
on the presence of jaundice, dark urine, light stools and 
Figure 1. An ultrasonographic study revealed enlargement 
of the gallbladder (vesica felea hydrops) and obstruction 
of the distal common bile duct 
bilirubinuria. The patient was believed to have 
anemia due to chronic bleeding (melena), de- 
ficiency or anemia in chronic disease. 
On the fourth day, the pain worsened, ac- 
companied by fever and chills and increased 
leukocyte count. The patient was considered 
to have cholangitis and 2 x 60 mg of 
Gentamycin was added. Total bilirubin was 
27.4 mg/dL, with direct and indirect bilirubin 
14.5 and 12.9, respectively. Alanine ami- 
notransferase was 124 U/L; aspartate ami- 
notransferase was 51 U/L; phospatase alka- 
line was 1717 U/L; gamma glutamil transferase 
was 364 U/L; and HBsAg was positive. Oc- 
cult blood test turned out negative. An 
ultrasonographic study revealed enlargement 
of the left lobe of the liver, enlargement of the 
gallbladder (vesica felea hydrops) and obstruc- 
tion of the distal common bile duct due to a 
certain mass (either stones or carcinoma of 
the pancreas).  
Figure 2. An esophagogastroduodenoscopy showed tumor of the pa- An esophagogastroduodenoscopy showed 
pilla vateri tumor of the papilla vateri. Pathologic exami- 
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Table 3. Urinary laboratory values 
 On 
admission 
Fourth 
hospital day 
 1.015 1.010 
pH 7 7 
Protein Trace - 
Glucose - - 
Acetone - - 
Blood - - 
Bilirubin +2 +3 
Urobilinogen 4 4 
Bacteria - - 
Epitel + + 
Leukocyte/high power field 1-2 4–5 
Erythrocyte/high power field 0-1 - 
Cylinder - - 
Crystal - - 
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nation showed well-differentiated adenocarcinoma of the
pancreas.
On the tenth day, the patient underwent explorative
laparotomy, cholecystectomy and T-tube insertion. There
was tumor mass on the head of the pancreas. The pa-
tient was then admitted to the surgical ward.
Pathologic finding from the operation revealed ad-
enocarcinoma with moderate to good differentiation.
Some of tumor cells had differentiated into signet ring
cell carcinoma. Immunoserologic measurement for CA
19-9 showed a more than two-fold increase (97.2 U/
ZL; normal <37 U/L).
The patient underwent her second operation a month
after the first operation. The Whipple procedure
(pancreaticoduodenectomy) was performed. A mobile
tumor was found at the head of the pancreas, 4x5 cm2 in
size. There was no lymphatic enlargement. The patient
then went home in good condition.
Two month afterwards, the patient was readmitted
to the hospital due tosevere abdominal pain. CT scan
and ultrasonographic study showed relapsing carcinoma
of the head of the pancreas, ascites and paraaortic lym-
phatic enlargement. The tumor was unresectable, and
the patient was treated in pain center with morphine.
The patient died a month afterwards at her home in
Serang.
DISCUSSION
Adenocarcinoma of the pancreas in a 26 year-old
woman like this patient is a rare case, because the dis-
ease usually arises after the age of 45 with a sharp in-
crease in occurrence thereafter.3,5
The possible risk factor for development of carci-
noma of the pancreas in this patient cannot be deter-
mined. She lived in a village away from industries, had
Figure 3. Pathologic examination showed adenocarcinoma
of the pancreas with moderate to good differentiation.
Some of tumor cells had differentiated into signet ring cell.
neither a history of high intake of fat or excessive eat-
ing, pancreatitis, nor diabetes mellitus.1-6 Even though
she was a passive smoker, the risk for pancreatic can-
cer increases to excess risk levels of 10 to 15 years
after smoking cessation.3 But this patient had a history
of carcinoma in her family. Genetic factors might also
have played a role in this patient.
Clinical features of this patient were actually almost
specific for carcinoma of the head of the pancreas. This
patient showed weight loss, pain, jaundice, dark, urine,
light stools, and pruritus. In a jaundiced patient without
obvious acute cholecystitis, a palpable gallbladder also
suggest a malignant tumor.14 Liver function tests showed
a total bilirubin value of 27.4 mg per 100 mL, and a pat-
tern corresponding with obstructive jaundice.
The history of melena that caused anemia in this pa-
tient indicated gastrointestinal bleeding, which might be
due to alternative medicine or a rare sign of pancreatic
carcinoma.2
The diagnosis of carcinoma of the pancreas was made
based on ultrasonographic, endoscopic, pathologic find-
ings, and an increased level of CA 19-9.
The patient had undergone two surgeries. The first
one was biliary stent placement to relieve jaundice and
cholecystectomy. The first surgery could also be used to
justify the stage of the tumor and for planning therapy.
Demonstration of probable resectability would lead to
consideration of chemotherapy and split-course radia-
tion therapy to reduce intra-operative dissemination of
the cancer and to increase chances for survival.7,15 Re-
sectability can be improved upon careful preoperative
assessment using imaging techniques such as computed
tomography, magnetic resonance imaging or endoscopic
and laparoscopic ultrasonography. Thirty to forty per-
cent of patients with potentially resectable cancer
evaluted were found to have liver metastases and peri-
toneal spread unseen by conventional computed tomog-
raphy or ultrasonography.13
The second surgery was elective Whipple
pancreatoduodenectomy procedure for removing the
carcinoma. This procedure is still considered as the gold
standard for pancreatic carcinoma.2,12,13
Prognostic factors determining survival after surgery
are the size of the tumor, grade, lymph node enlarge-
ment, and staging. It is unanimously accepted that in or-
der to improve the chances of survival in patients with
pancreatic carcinoma, radical surgical procedures should
be extended to include lymphadenectomy. Postopera-
tive adjuvant therapy could also be a determinant fac-
tor.13 Unfortunately, this patient did not undergo radio-
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therapy or chemotherapy.
The patient died five months after she was diagnosed
with pancreatic cancer. This was longer than the me-
dian survival time reported (3 months).2 Actually, at the
time of diagnosis, over 85 percent of tumors have ex-
tended beyond the organ.2,4 Even today pancreatic can-
cer should be considered as incurable, since even after
radical surgery, the majority of the patients die from the
consequences of the disease.13
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